Memorial Hospital Research Laboratories

The Luke Pike Lab

Share
Back to top

Research

Luke Pike
Luke Pike, MD, DPhil

The Luke Pike Lab seeks to understand the unique biology of brain metastasis (BrM) and to improve outcomes for patients afflicted with this terrible disease. BrM is an exceptionally common form of solid tumor metastasis, affecting approximately 400,000 U.S. cancer patients each year. The mechanisms by which cancer cells spread to and survive in the brain are poorly understood. A highly effective treatment for BrM is a form of radiation therapy called stereotactic radiosurgery. However, in recent years, new drugs have been developed with potential activity against BrM. The Pike Lab uses cutting-edge molecular techniques to understand tumor tropism for the brain and to identify features of human BM that might lead to drug or radiation resistance. We also seek to take these insights from the “bench to the bedside” through novel clinical trials and translational research studies that combine radiotherapy and new CNS-active drugs and identify biomarkers that may help guide therapeutic selection.

Luke Pike Lab group outing

Publications Highlights

Skakodub A, Tringale KR, Walch HS, Vasudevan H, Eichholz J, Kelly D, Moss NS, Yu KKH, Li BT, Mueller B, Yang JT, Beal K, Imber BS, Gomez DR, Schultz N, Pike LRG. Genomic analysis and clinical correlations of non-small cell lung cancer (NSCLC) brain metastasis (BM). Journal of Clinical Oncology 2022 40:16_suppl, 2008-2008.

Hwang WL*, Pike LRG*, Royce TJ, Mahal BA, Loeffler JS. Safety of combining radiotherapy with immune-checkpoint inhibition. Nat Rev Clin Oncol. 2018 Aug;15(8):477-494. doi: 10.1038/s41571-018-0046-7. Review. *Co-first authors.

Pike LRG, Bang A, Ott P, Balboni T, Taylor A, Catalano P, Rawal B, Spektor A, Krishnan M, Cagney D, Alexander B, Aizer AA, Buchbinder E, Awad M, Gandhi L, Hodi FS, Schoenfeld JD. Radiation and PD-1 inhibition: Favorable outcomes after brain-directed radiation. Radiother Oncol. 2017 Jul;124(1):98-103. doi: 10.1016/j.radonc.2017.06.006. Epub 2017 Jun 26.

View All Publications

People

Luke Pike

Luke Pike, MD, DPhil

  • Physician-scientist Luke R.G. Pike studies the mechanistic underpinnings of brain metastasis and seeks to identify translational correlates with outcomes following local or systemic therapy.
  • DPhil/PhD, Medical Oncology, University of Oxford
  • MD, Yale School of Medicine
PikeL@mskcc.org
Email Address
View physician profile
Physician profile

Members

Kevin Boehm
Kevin M. Boehm

Postdoctoral Fellow, Computational Oncology; Resident Physician, Radiation Oncology

Gustav Cederquist

Memorial Sloan Kettering RO PGY3

Claire Cooper

Intern

Luke del Balzo
Luke del Balzo

Medical College of Georgia MS3

Jordan Eichholz
Jordan Eichholz

Project Coordinator

Benjamin Gaeta
Benjamin Gaeta

Cornell MS3

Rebekah Goetz

Research Project Associate

Chengcheng Gui
Chengcheng Gui

Memorial Sloan Kettering RO PGY3

Ishaani Khatri
Ishaani Khatri

Brown MS2

Rahul Kumar

Undergraduate, University of Miami

Emily Lebow
Emily Lebow

Memorial Sloan Kettering RO PGY5

James Lee
Jennifer Ma
Jennifer Ma

Memorial Sloan Kettering RO PGY4

Amandeep R. Mahal

Harvard Radiation Oncology Program, PGY3

Michel Padilla Mazzeo
Emily Miao
Emily Miao

Albert Einstein MS3

Kirin Mueller

Yale Undergrad

Mitchell Parker
Junchao Shen
Anna Skakodub
Anna Skakodub

Pennsylvania State College of Medicine MS3

Kathryn Tringale
Kathryn Tringale

Memorial Sloan Kettering RO PGY5

Ross Weber

Memorial Sloan Kettering PGY1

Emily Wo
Lab Alumni
Alexi Dreyfuss

Memorial Sloan Kettering RO PGY3

Lab Affiliations

Achievements

  • Alexander Graham Bell PhD Scholarship (2009)
  • The Rhodes Scholarship (2007)

Open Positions

To learn more about available postdoctoral opportunities, please visit our Career Center

To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs

Get in Touch

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Luke Pike discloses the following relationships and financial interests:

  • Dxcover Limited
    Professional Services and Activities (Uncompensated)
  • Genece Health, Inc.
    Professional Services and Activities (Uncompensated)
  • Monograph Capital Advisors, L.P.
    Professional Services and Activities

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.


View all disclosures